Ftse Mib
34.997,90
-1,13%
DAX
18.759,19
0,28%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.775,29
0,93%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Minerva Neurosciences Inc (NERV) Minerva Neurosciences Inc (NERV) Notizie

NERV

Minerva Neurosciences (NERV)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NERV
DataOraFonteTitoloSimboloCompagnia
01/05/202413:30GlobeNewswire Inc.Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
27/02/202414:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NERVMinerva Neurosciences Inc
27/02/202414:00GlobeNewswire Inc.Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with SchizophreniaNASDAQ:NERVMinerva Neurosciences Inc
22/02/202413:00GlobeNewswire Inc.Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
22/02/202412:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NERVMinerva Neurosciences Inc
07/11/202313:30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
07/11/202313:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NERVMinerva Neurosciences Inc
05/10/202322:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NERVMinerva Neurosciences Inc
15/08/202315:28Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NERVMinerva Neurosciences Inc
15/08/202315:26Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NERVMinerva Neurosciences Inc
15/08/202315:25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NERVMinerva Neurosciences Inc
10/08/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NERVMinerva Neurosciences Inc
09/08/202323:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NERVMinerva Neurosciences Inc
04/08/202314:07Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:NERVMinerva Neurosciences Inc
01/08/202313:30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
07/07/202322:18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NERVMinerva Neurosciences Inc
03/07/202322:04Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:NERVMinerva Neurosciences Inc
28/06/202314:38Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NERVMinerva Neurosciences Inc
28/06/202314:30GlobeNewswire Inc.Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to MarketNASDAQ:NERVMinerva Neurosciences Inc
15/05/202313:30GlobeNewswire Inc.Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
15/05/202313:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NERVMinerva Neurosciences Inc
10/05/202314:00GlobeNewswire Inc.Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaNASDAQ:NERVMinerva Neurosciences Inc
08/05/202314:30GlobeNewswire Inc.Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023NASDAQ:NERVMinerva Neurosciences Inc
03/05/202300:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NERVMinerva Neurosciences Inc
01/05/202313:00GlobeNewswire Inc.Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in SchizophreniaNASDAQ:NERVMinerva Neurosciences Inc
08/03/202313:30GlobeNewswire Inc.Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business UpdatesNASDAQ:NERVMinerva Neurosciences Inc
01/03/202314:30GlobeNewswire Inc.Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023NASDAQ:NERVMinerva Neurosciences Inc
14/02/202322:14Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NERVMinerva Neurosciences Inc
10/11/202212:16TipRanksMinerva Neurosciences (NERV) Receives a Buy from BTIGNASDAQ:NERVMinerva Neurosciences Inc
09/11/202218:30TipRanksAnalysts Offer Insights on Healthcare Companies: GlycoMimetics (GLYC) and Minerva Neurosciences (NERV)NASDAQ:NERVMinerva Neurosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NERV

La tua Cronologia

BIT
P1V223
NLBNPIT1V223 20991231 27...
COIN
BONKOUSD
BONKTOKEN [OLD]
USOTC
GIAF
GigCapital 5 (PK)
COIN
BZNUSD
Benzene
HITB
LITUSDT
Litentry
LSE
CA3S
Ivz Chna A 300
BIT
P1UYK8
NLBNPIT1UYK8 20991231 10...
LSE
56TJ
Akademiska 38
EU
D286T
D286T
BIT
Q00552
Leonteq Securities
LSE
45KH
Malmo 39
TKOK
BCHUSDT
Bitcoin Cash
USOTC
FNDM
Fund com (CE)
LSE
1061
USOTC
GIAFW
GigCapital 5 (PK)
NASDAQ
FHWNBX
Senior Loan ClosedEnd an...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network